These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 32745350)

  • 1. Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study.
    Gontero P; Montanari E; Roupret M; Longo F; Stockley J; Kennedy A; Rodriguez O; McCracken SRC; Dudderidge T; Sieverink C; Vanié F; Allasia M; Witjes JA; Sylvester R; Colombel M; Palou J
    BJU Int; 2021 Feb; 127(2):198-204. PubMed ID: 32745350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review.
    Wolfs JRE; Hermans TJN; Koldewijn EL; van de Kerkhof D
    Urol Oncol; 2021 Mar; 39(3):161-170. PubMed ID: 33376063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MCM5 urine expression (ADXBLADDER) is a reliable biomarker of high-risk non- muscle-invasive bladder cancer recurrence: A prospective matched case-control study.
    Białek Ł; Czerwińska K; Fus Ł; Krajewski W; Sadowska A; Radziszewski P; Dobruch J; Kryst P; Poletajew S
    Cancer Biomark; 2021; 30(2):139-143. PubMed ID: 32924986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel, non-invasive Test Enabling Bladder Cancer Detection in Urine Sediment of Patients Presenting with Haematuria-A Prospective Multicentre Performance Evaluation of ADXBLADDER.
    Dudderidge T; Stockley J; Nabi G; Mom J; Umez-Eronini N; Hrouda D; Cresswell J; McCracken SRC
    Eur Urol Oncol; 2020 Feb; 3(1):42-46. PubMed ID: 31307961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Accuracy of MCM5 for the Detection of Recurrence in Nonmuscle Invasive Bladder Cancer Followup: A Blinded, Prospective Cohort, Multicenter European Study.
    Roupret M; Gontero P; McCracken SRC; Dudderidge T; Stockley J; Kennedy A; Rodriguez O; Sieverink C; Vanié F; Allasia M; Witjes JA; Colombel M; Sylvester R; Longo F; Montanari E; Palou J
    J Urol; 2020 Oct; 204(4):685-690. PubMed ID: 32314931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing the Frequency of Follow-up Cystoscopy in Low-grade pTa Non-muscle-invasive Bladder Cancer Using the ADXBLADDER Biomarker.
    Rouprêt M; Gontero P; McCracken SRC; Dudderidge T; Stockley J; Kennedy A; Rodriguez O; Sieverink C; Vanié F; Allasia M; Witjes JA; Colombel M; Longo F; Montanari E; Palou J; Sylvester RJ
    Eur Urol Focus; 2022 Nov; 8(6):1643-1649. PubMed ID: 35300937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
    Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
    Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of MCM5 (ADXBLADDER) analysis in urine of men evaluated for the initial diagnosis of bladder cancer: A comparative prospective study.
    Anastasi E; Maggi M; Tartaglione S; Angeloni A; Gennarini G; Leoncini PP; Sperduti I; Di Lascio G; De Stefano V; Di Pierro GB; Del Giudice F; Busetto GM; De Berardinis E; Sciarra A
    Diagn Cytopathol; 2020 Nov; 48(11):1034-1040. PubMed ID: 32562513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
    Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
    BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert
    Cowan B; Klein E; Jansz K; Westenfelder K; Bradford T; Peterson C; Scherr D; Karsh LI; Egerdie B; Witjes A; Trainer A; Harris R; Goldfarb B; Flax S; Kroeger R; Boyd B; Liao J; Patel S; Bridge J; Reuter V; Quigley N; Brown S; Zhao S; Satya M; Bates M; Simon IM; Campbell S; Lotan Y
    BJU Int; 2021 Dec; 128(6):713-721. PubMed ID: 33793062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up: a systematic review.
    Soorojebally Y; Neuzillet Y; Roumiguié M; Lamy PJ; Allory Y; Descotes F; Ferlicot S; Kassab-Chahmi D; Oudard S; Rébillard X; Roy C; Lebret T; Rouprêt M; Audenet F
    World J Urol; 2023 Feb; 41(2):345-359. PubMed ID: 36592175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Validation of Clinical Usefulness of a Novel mRNA-based Urine Test (Xpert® Bladder Cancer Monitor) for surveillance in Non Muscle Invasive Bladder Cancer.
    Elsawy AA; Awadalla A; Elsayed A; Abdullateef M; Abol-Enein H
    Urol Oncol; 2021 Jan; 39(1):77.e9-77.e16. PubMed ID: 32800441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does urinary cytology have a role in haematuria investigations?
    Tan WS; Sarpong R; Khetrapal P; Rodney S; Mostafid H; Cresswell J; Watson D; Rane A; Hicks J; Hellawell G; Davies M; Srirangam SJ; Dawson L; Payne D; Williams N; Brew-Graves C; Feber A; Kelly JD;
    BJU Int; 2019 Jan; 123(1):74-81. PubMed ID: 30003675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts.
    Brems-Eskildsen AS; Zieger K; Toldbod H; Holcomb C; Higuchi R; Mansilla F; Munksgaard PP; Borre M; Ørntoft TF; Dyrskjøt L
    BMC Cancer; 2010 Nov; 10():646. PubMed ID: 21106093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.
    Raitanen MP;
    World J Urol; 2008 Feb; 26(1):45-50. PubMed ID: 18180926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer.
    Karaoglu I; van der Heijden AG; Witjes JA
    World J Urol; 2014 Jun; 32(3):651-9. PubMed ID: 24166285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
    Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
    Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer.
    Trenti E; D'Elia C; Mian C; Schwienbacher C; Hanspeter E; Pycha A; Kafka M; Degener S; Danuser H; Roth S; Pycha A
    Cancer Cytopathol; 2019 Jul; 127(7):465-469. PubMed ID: 31154670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.
    Beukers W; van der Keur KA; Kandimalla R; Vergouwe Y; Steyerberg EW; Boormans JL; Jensen JB; Lorente JA; Real FX; Segersten U; Orntoft TF; Malats N; Malmström PU; Dyrskjot L; Zwarthoff EC
    J Urol; 2017 Jun; 197(6):1410-1418. PubMed ID: 28049011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
    Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
    Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.